, , ,

<<


 >>  ()
Pages:     | 1 |   ...   | 2 | 3 ||

һ ...

-- [ 4 ] --

244. For the Atherosclerosis Risk in communities (ARIC) Study Investigators Relation of carotid artery wall thikness to diabetes mellitus, fasting glucose and insu lin, body size, and physical activity / A.R. Folsom, J.H. Eckfeldt, S. Weitzman [et al.] // Stroke. 1994. Vol. 25. P. 66-73.

245. Fredrickson, DS. A system for phenotyping hyperlipoproteinemia/ D.

Fredrickson, R. Lees // Circulation. 1965.Vol. 31. P. 321-327.

246. Friedewald, W.T. Estimation on the concentration of low-density lipo protein cholesterol in plasma without use of the preparative ultracentrifuge / W.T.

Friedewald, R.I. Levy, D.S. Freidricksen // Clin. Chem. 1972. Vol. 18. P. 499-502.

247. Grines, C.L. The role of statins in reversing atherosclerosis: what the lat est regression studies show /C.L. Grines //J. Interv. Cardiol. 2006. Vol. 19. P. 3-9.

248. Haller H. Endothelial function. General considerations / H. Haller // Drugs. 1997. Vol. 53 (Suppl 1). P. 1-10.

249. Heart Protection Study Collaborative Group. MRC/BHR Heart Protec tion Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial // Lancet. 2002. Vol.360. P. 7-22.

250. Heinecke, J.W. Free radical modification of low density lipoprotein:

mechanismand biological conseguences / J.W. Heinecke // Free Rad.Biol. Med. 1987. Vol. 3. P.65-73.

251. High dose atorvastatin vs usual dose simvastatin for secondary preven tion after myocardial infarction / T.R. Pedersen, O. Faergeman, J.P. Kastelein [et al.] // JAMA. 2005. Vol. 294, N 19. P. 2437-2445.

252. High-dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients / S.L.

Brown, F.J. Raal, V.R. Panz [et al.] // Cardiovasc. J. South. Africa. 2004. Vol. 15, N 2. P. 70-75.

253. Howes, L.G. The effects of lipid-lowering drug therapy on cardiovascu lar responsiveness in type 2 diabetic patients / L.G. Howes // Diabetes Obes. Metab. 2006. Vol. 8, N 1. P. 8-14.

254. Human lymphocytes synthesize C-reactive protein / T. Ikuta, H. Okubo, H. Ishibashi [et al.] // Inflammation. 1986. Vol. 10. P. 223-232.

255. Hydroxymethylglutarylcoenzyme A reductase inhibition promotes en dothelial nitric oxide synthase activation through a decrease in caveolin abundance / O. Feron, C. Dessy, J.P. Desager [et al.] // Circulation. 2001. Vol. 103. P. 113-118.

256. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits / S.J. Nicholls, B. Cutri, S.G. Worthley [et al.] // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 2416-2421.

257. Improvement of nitric oxidedependent vasodilation by HMGCoA re ductase inhibitors through attenuation of endothelial superoxide anion formation / A.H. Wagner, T. Kohler, U. Ruckschloss [et al.] // Arterioscler. Thromb. Vasc. Biol.

2000. Vol. 20. P. 61-69.

258. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study / S. Kathiresan, J.D. Otvos, M.L. Sullivan [et al.] // Circulation. 2006. Vol. 113. P. 20-29.

259. Independent prognostic value of C-reactive protein and troponin I in pa tients with unstable angina or non-Q-wave myocardial infarction / R.L. de Winter, R.

Bholasigh, J.G. Lijmer [et al.] // Cardiovasc. Res. 1999. Vol. 42. P. 240-245.

260. Inflammation, endothelium, andcoagulation in sepsis/ M. Schouten, W.J.

Wiersinga, M. Levi, T. van der Poll // J. Leukoc. Biol. 2008. Vol. 83, N 3. P. 536-545.

261. Influence of atorvastatin treatment on L-arginine cerebrovascular reac tivity and flow-mediated dilatation in patients with lacunar infarctions / J. Pretnar Oblak, M. Sabovic, M. Sebestjen [et al.] // Stroke. 2006.Vol. 37.P. 2540-2545.

262. Influence of prolonged statin therapy on the arterial distensibility in sta ble ischemic heart disease / M. Kurpesa, M. Tyminski, E. Trzos [et al.]// Przegl. Lek.

2005. Vol. 62, N 4. P. 210-213.

263. Intensive lipid lowering with atorvastatin in patients with stable coronary disease / J.C. LaRosa, S.M. Grundy, D.D. Waters // N. Engl. J. Med. 2005. Vol.

352, N 14. P. 1425-1435.

264. Jones, P.H. Comparison of the efficacy and safety of atorvastatin in itiated at different starting doses in patients with dyslipidemia / P.H. Jones, J.M.

McKenney, D.G. Karalis// Evide. Based Cardiovasc. Med. 2005. Vol. 9, N 2. P. 98-101.

265. Kaplan, N.M. The ASCOT trial: a closer look / N.M. Kaplan // J. Hyper tens. 2006. Vol. 24, N 2. P. 211-214.

266. Kappagoda, C.T. Another look at the results of the JUPITER trial / C.T.

Kappagoda, E.A. Amsterdam // Am. J. Cardiol. 2009. Vol. 104, N 11. P. 1603-1605.

267. Karalis, D.G. Comparison of efficacy and safety of atorvastatin and sim vastatin in patients with dyslipidemia with and without coronary heart disease / D.G.

Karalis, A.M. Ross, R.M. Vacari // Am. J. Cardiol. 2002. Vol. 89, N 6. P. 667-671.

268. Kastelein, J. Surrogate markers of atherosclerosis: impact of statins / J.

Kastelein, A. Wiegman, E. de Groot // Atherosclerosis. 2003 (Suppl 4). P. 31-36.

269. Kastle, T. Potentiation of nitric oxide mediated vascular relacsation by superoxide dismutase mimic / T. Kastle, S. Settle, T. Mako // Proc. Soc. Exp. Bi ol.Med. 1995. Vol. 208. P. 170-177.

270. Kazuhiro, S. Expression and regulation of endothelial nitric oxide syn thase / S. Kazuhiro, T. Michel // TCM. 1997. Vol. 7, N 1. P. 28-37.

271. Kekes E., Csaszar . Testing the antilipid properties of rosuvastatin a noninterventional, observational clinical study (TIGER) // Cardiol. Hungarica. 2012.

Vol. 422. P. 6167.

272. Keller R. et al. Defined daily doses in relation to hypolipidemic effect of lovastatin, pravastatin and simvastatin. // Lancet. 1994. V. 343. .1554 273. LaRosa, J.C. Effect of statins on risk of coronary disease: A meta analysis of randomized controlled trials / J.C. LaRosa, H. Jiang, S. Vupputuri // JA MA, Dec 1999. Vol. 282. P. 23402346.

274. Laufs, U. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)CoA reduc tase blocks hypoxiamediated downregulation of endothelial nitric oxide synthase / U. Laufs, V.L. La Fata, J.K. Liao // J. Biol. Chem. 1997. Vol. 272. P. 31725 31729.

275. Ledue, T. Preanalytic and analytic sources of variations in CRP mea surement: implications of cardiovascular disease risk assessment / T. Ledue, N. Rifai // Clin. Chem. 2003. Vol.49,N 8. P. 1258-1271.

276. Lewis, G.F. New insights into the regulation of HDL metabolism and re verse cholesterol transport / G.F. Lewis, D.L. Rader // Circ. Res. 2005. Vol. 96. P. 1221-1232.

277. Lifestyle and risk factor management and use of drug therapies inn coro nary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programm // Eur. Heart J. 2001. Vol. 22. P. 554-572.

278. Lipidmodifying therapy and attainment of cholesterol goals in Eu rope:the Return on Expenditure Achieved for Lipid Therapy (REALITY) study / E.

Ganse van, L. Laforest,E. Alemao [et al.] // Curr. Med. Res. Opin. 2005. Vol. 21, N 9. P. 1389-1399.

279. Lipoprotein particle concentrations may explain the absence of coronary protection in the Womens Health Initiative Hormone Trials / J. Hsia, J.D. Otvos, J.E.

Rossouw [et al.] // Arterioscler. Thromb. Vasc. Biol. 2008. Vol. 28. P. 1666-1671.

280. Lipoprotein(a), fibrin binding, and plasminogen activation / J. Loscalzo, M. Weunfeld, G.M. Fless, A.M. Scanu //Arteriosclerosis.1990. N 10. P. 240-246.

281. Low-density lipoprotein particle concentration and size as determined by NMR spectroscopy as predictors of cardiovascular disease in women / G.J. Blake, J.D. Otvos, N. Rifai, P.J. Ridker // Circulation. 2002. Vol. 106. P. 1930-1937.

282. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men13-year follow-up data from the Quebec Cardiovascular Study / A. St-Pierre, B. Cantin, G.R. Dagenais [et al.] // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 553-559.

283. Lp(a) lipoprotein as a risk factor for myocardialinfarction / G.G. Rhoads, G. Dahlen, K. Berg [et al.] // JAMA. 1986. Vol. 256. P. 2540-2544.

284. Luscher T.F., Tanner F.C., Noll G. Lipids and endothelial function: ef fects of lipid lowering and therapeutic intervention / T.F. Luscher, F.C. Tanner, G.D.

Noll // Curr. Opin. Lipidol. 1996. N 7. P. 234-240.

285. Luscher, T.F. The pathogenesis of cardiovascular disease: role of the en dothelium as a target and mediator / T.F. Luscher, G.D. Noll // Atherosclerosis. 1995. Vol. 118 (Suppl.). P. S81-S90.

286. Mackenzie, I.S. Assessment of arterial stiffness in clinical practice / I.S.

Mackenzie, I.B. Wilkinson, J.R. Cockcroft // Q. J. Med. 2002. Vol. 95. P. 67-74.

287. Malondialdehyde alteration of LDL leads to cholesterol ester accumula tion in human monocytes/macrophages / A.M. Fogelman, J.A. Berliner, M. Navab [et al.] // Proc. Natl. Acad. Sci.(USA). 1980 Vol. 77. P. 2214-2218.

288. Mikhailidis, D.P. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study / D.P. Mikhailidis, A.S. Wierzbicki // Curr. Med. Res.

Opin. 2002. Vol. 18, N 4. P. 215-219.

289. Mizuno, K.Y. A randomized, openlabel, comparative study of simvas tatin plus diet versus diet alone on angiographic retardation of coronary atherosclero sis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study / K. Mizuno, H. Nakamura, Y. Ohashi // Clin. Ther. 2004. Vol. 26. P. 878-888.

290. Multiple coronary heart disease risk factors are associated with meno pause and influenced by substitutive hormonal therapy in a cohort of French women / J. Dallongeville, N. Marecaux, D. Isorez [et al.] // Atherosclerosis. 1995. Vol. 118.

P. 123-133.

291. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering.

(MIRACLE) study Investigators. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACLE study: a randomized controlled trial / G.G. Schwartz, A.G. Ollson, M.D. Ezekowitz [et al.] // JAMA. 2001. Vol.

285. N 13. P. 1711-1718.

292. Naito, K.N. Lipids / K.N. Naito // Clin Chem / A. Kaplan [et al.]. The C.V. Mosby Co. St Louis. Toronto. Princeton, 1984. P. 918-919;

570-572.

293. Nakamura, H. Predictive value of cardiovascular events by high sensitiv ity CRP / H. Nakamura, T. Yamashita // Nippon. Rinsho. 2002. Vol. 60, N 5. P.

916-921.

294. National guidelines for the All-Russian Scientific Society for Cardiovas cular Prevention // Cardiovasc. Ther. Prevention. 2011. Vol. 10, N 6 (Suppl. 2). P. 64.

295. Nichols, W.W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms / W.W. Nichols // Am. J. Hypertens. 2005. Vol.18. P. 3S-10S.

296. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men / P. Pignoli, E. Tremoli, A. Poli [et al.] // Circulation. 2005. Vol. 112. P. 3375-3383.

297. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis / D.S. Celermajer, K.E. Sorensen, V.M. Gooch [et al.] // Lancet. 1992. Vol. 340. P. 1111-1115.

298. Oganov, R.G.Prevention of cardiovascular disease: the development / R.G. Oganov,N.F. Gerasimenko, G.V. Pogosova // Cardiovasc. Ther. Prevention. 2011. N 3. P. 5-7.

299. Or,Rourke, M.F. Arterial function in health and disease / M.F.

Or,Rourke. Edinburgh: Churchill, 1982. 288 p.

300. Oreste, P.Intimal plus medial thickness of arterial wall: the direct mea surement with ultrasound imaging / P. Oreste, R. Paoletti // Circulation. 1986. Vol.

74. P. 1339-1408.

301. Otvos, J.D. Measurement issues related to lipoprotein heterogeneity / J.D. Otvos, E.J. Jeyarajah, W.C. Cromwell // Am. J. Cardiology. 2002. Vol. (Suppl.). P. 22-29.

302. Palomaki, A. Ubiquinone supplementation during lovastatin treatment:

effect on LDL oxidation ex vivo / A. Palomaki, K. Malminiemi, T. Solakivi // J. Li pid. Res. 1998. Vol. 39. P. 1430-1437.

303. Pasceri, V.Direct proinflammatory effect of C-reactive protein on human endothelial cells / V. Pasceri, J.T. Willerson, E.T.H. Yeh // Circulation. 2000. Vol. 102. P. 2165-2168.

304. Pepys, M.B. C reactive protein: a critical update / M.B. Pepys, G.M.

Hirschfield // J. Clin. Invest. 2003. Vol. 11. P. 1805-1812.

305. Pravastatin or Atorvastatin evaluation and infection therapy thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate li pidlowering with statins after acute coronary syndromes / C.P. Cannon, E. Braun wald, C.H. McCabe [et al.] // N. Engl. J. Med. 2004. Vol. 350. P. 1495-1504.

306. Prediction of mechanical properties of human atherosclerotic tissue by high-frequency intravascular ultrasound imaging: an in vitro study / R.T. Lee, G.

Richardson, H.M. Loree [et al.] // Arterioscler. Thromb. Vase. Biol. 1992. Vol.

12. P.1-5.

307. Preservation of NO production by statins in the treatment of heart failure / J.N. Trochu, S. Mital, X. Zhang [et al.]// Cardiovasc. Res. 2003. Vol. 60. P. 250-258.

308. Prevention of coronary heart disease with pravastatin in men with hyper cholesterolemia / J. Shepherd, S.M. Cobbe, I. Ford [et al.] // N. Engl. J. Med. 1995.

Vol. 333. P. 1301-1307.

309. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS / J.R. Downs, M. Clearfield, S. Weis [t al.] // JAMA 2001. Vol. 279. P. 1615-22.

310. Primary prevention of cardiovascular disease with atorvastatin in type diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre ran domised placebocontrolled trial / H.M. Collhoun, D.J. Betteridge, P.N. Durrington [et al.] // Lancet. 2004. Vol. 364, N 9435. P. 685-696.

311. Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty / H.K. Yip, C.J.

Wu, H.W. Chang [et al.] // Chest. 2005. Vol. 127. P. 1491-1497.

312. Prospective study of endogenous tissue plasminogen activator and risk of stroke / P.M. Ridker, C.H. Hennekens, M.J. Stampfer [et al.] // Lancet. 1994. Vol.

343. P. 940-943.

313. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) // Lancet. 1994. Vol. 344. P. 1383-1389.

314. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhi bition on coronary endothelial function / S. Wassmann, A. Faul, B. Hennen [et al.] // Circ. Res. 2003. Vol. 93, N 9. P. 98-103.

315. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA) / P.S. Sever, N.R. Poulter, B. Dahlof [et al.] // Diabetes Care. 2005. Vol. 28, N 5. P. 1151-1157.

316. Relation of left ventricular concentric remodeling to levels of C reac tive protein and serum amyloid A in patients with essential hypertension / C. Tsiou fis, P. Stougiannos, A. Kakkavas [et al.] // Am. J. Cardiology. 2005. Vol. 96, N 2.

P. 252-256.

317. Relationship between uncontrolled risk-factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial / K.K. Ray, C.P. Cannon, R. Cairns [et al.] // JACC 2005. Vol. 46, N 8. P. 1417-1424.

318. Remuzzi, G. Endothelins in the control of cardiovascular and renal func tion / G. Remuzzi, M.A. Polokoff // Lancet. 1993. Vol. 342. P. 589-592.

319. Ridker, P.M. C-reactive protein: eighty years from discovery to emer gence as a major risk marker for cardiovascular disease / P.M. Ridker // Clin. Chemi stry. 2009. Vol. 55. P. 209-215.

320. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflamma tion, and the risk of coronary heart disease. Circulation. 2000. Vol. 101. P. 252- 321. Rosuvastatin to prevent vascular event in men and women with elevated C-reactive protein / P. Ridker [et al.] // N.J. Med. 2008. Vol. 359. P. 2196-2207.

322. Rubanyi, G.M. Enlothelin: moleculer biology biochimistuy. Pharmaco lagy, physiology and pthophysiology / G.M. Rubaniy, M.A. Polokofe // Pharmacol.

Rew. 1994. Vol. 46. .325-415.

323. Rubanyi, G.M. The role of endothelium in cardiovascular homeostasis and diseases / G.M. Rubanyi // J. Cardiovasc. Pharmacol. 1993. Vol. 22 (Suppl.

4). P. S1-S4.

324. Salonen, R. Measurement of intima-media thickness of common carotid arteries with high resolution B-mode ultrasonography: inter and intraobsever variabil ity / R. Salonen, A. Hapenen, J.M. Salonen // Ultrasound Med. Biol. 1991. Vol.

17. P. 225-230.

325. Salonen, R. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study / R. Salonen, J.T. Salonen // Atherosclerosis.

1990. Vol. 81, N 1. P. 33-40.

326. Shirai, K. A New World of Vascular Function Developed by CAVI / K.

Shirai // CAVI as a novel indicatior of vascular function. Japan : Toho University, 2009. . 16-29.

327. Simvastatin exerts both antiinflammatory and cardioprotective effects in apolipoprotein E deficient mice / R. Scalia, M.E. Gooszen, S.P. Jones [et al.] // Circulation. 2001. Vol. 103. P. 2598-2603.

328. Simvastatin restores endothelial NOmediated vasorelaxation in large ar teries after myocardial infarction / K. Bates, C.E. Ruggeroli, S. Goldman, M.A. Ga balla // Am. J. Physiol. Heart. Circ. Physiol. 2002. Vol. 283. P. H768-H75.

329. Simvastatin with or without ezetimibe in familial hypercholesterolemia // N. Engl. J. Med. 2008. Vol. 358. P. 1431-1443.


330. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endo thelial function within 1 month / G. O'Driscoll, D. Green, R.R. Taylor // Circulation.

1997. Vol. 95. P. 1126- 331. Smoking cessation and decreased risk of stroke in women / L. Kowachi, G.A. Colditz, M.J. Stampfer [et al.] // JAMA. 1993. Vol. 269. P. 232-236.

332. Sniderman, A.D. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes / A.D. Sniderman, T. Scantlebury, K. Cianflone // Ann. Intern. Med. 2001. Vol. 135. P. 447-459.

333. Spatz, E.S. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey / E.S. Spatz, M.E. Canavan, M.M. Desai // Circ.Cardiovasc. Qual. Outcomes.

2009. N 2. P. 41-48.

334. Statin in stroke prevention and carotid atherosclerosis: systematic review and meta-analysis / P. Amarenco, J. Labreuche, P. Lavalle' e, Touboul, P.-J. // Stroke.

2004. Vol. 35. P. 2902-2909.

335. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease / S.E. Nissen,E. Tuzcu, P. Schoenhagen [et al.] // N. Engl. J. Med. 2005. Vol. 352, N 1. P. 29-38.

336. Steinberg, D. Beyond cholesterol: modifications of low densiry lipo protein thatincrease its atherogenecity / D. Steinberg, S. Parthhhaseramy, T. Carew // N. Engl. J. Med. 1989. Vol. 320. P. 915-924.

337. Steinberg, D. Oxidative modification of LDL and atherogenesis. / D.

Steinberg // Circulation. 1997. Vol. 95. P. 1062-1071.

338. Steinberg, D. Role of oxidized LDL and antioxidants in atherosclerosis / D. Steinberg // Nutrition and biotecnology in heart desease and cancer / ed.J.B. Lon genecker [et al.]. N.Y.: Plenum Press, 1995. P. 39-48.

339. Summury of the third report of the National Cholesterol Education Pro gram (NCEP) expert panel on detection, evaluation and treatment of high blood cho lesterol in adults (Adult Treatment Panel III) // JAMA. 2001. Vol. 285. P. 2486-2497.

340. Taneva, E. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal / E. Taneva, K. Borucki, L. Wiens // Am. J. Cardiol. 2006. Vol. 97, N 7. P. 1002-1006.

341. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia / T.J. Smilde, F.W. van den Berkmortel, H. Wollersheim [et al.] // Eur. J. Clin. Invest. 2000. Vol. 30, N 6. P. 473-480.

342. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS) / H.P. Bestehorn, U.F. Rensing, H.

Roskamm [t al.] // Eur. Heart J. 1997. Vol. 18. P. 226-234.

343. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease / E.D. Beishuizen, J.T. Tamsma, J.W. Juke ma [et al.] // Diabetes Care. 2005. Vol. 28, N 7. P. 1668-1674.

344. The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction / S. Hosokawa, Y. Hiasa, T. Tomokane [et al.] // Clin. Cardiol. 2006. Vol. 29, N 8. P. 357-362.

345. The effects of different doses of atorvastatin on plasma endothelin-1 le vels in type 2 diabetic patients with dyslipidemia / H.C. Lam, C.H. Chu, M.C. Wei [et al.] // Exp. Biol. Med. 2006. Vol. 231, N 6. P. 1010-1015.

346. The HMGCoA reductase inhibitors simvastatin activates the protein ki nase Akt and promotes angiogenesis in normocholesterolemic animals / Y. Kureishi, Z. Luo, I. Shiojima [et al.] // Nat. Med. 2000. N 6. P. 1004-1010.

347. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravas tation treatment on lipids, oxydation resistance of lipoproteins, and atherosclerotic progression / R. Salonen, K. Nysonen, E. Porkala-Sarataho, J. Salonen // Am. J. Car diol. 1995. Vol. 76. P. 34c-39c.

348. The pivotal role of endotelmm in hypertension / S. Taddei,A. Virdis, L.

Chiadoni, A. Salvetti // Medicographia. 1999. Vol. 21, N 1. P. 22-29.

349. The prognostic value of C-reactive protein and serum amiloid A with recurrent coronary events in stable patients after healing of acute myocardial infarc tion / G. Liuzzo, L.M. Biasucci, J.R. Gallimore [et al.] // Am. J. Cardiol. 2002. Vol. 89. P.216-221.

350. Triglycerides and the risk of coronary heart disease: 10,158 incident cas es among 262,525 participants in 29 Western prospective studies / N. Sarwar, J. Da nesh, G. Eiriksdottir [et al.] // Circulation. 2007. Vol. 115. P. 450-458.

351. Ultrasonographic manifestation of common carotid atherosclerosis in el dery Eastern Finish men. Prevalence and association with cardiovascular disease and risk factors /R. Salonen, M. Tervahauta, J.T. Salonen [et al.] // Arterioscler. Thromb.

1994. Vol. 14. P. 1631-1640.

352. Usefulness of brachial artery reactivity to isometric handgrip exercise in identifying patients at risk and with coronary artery disease / M. Rubenfire, N. Cao, D.E. Smith, L. Mosca // Am. J. Cardiol. 2000. Vol. 86, N 11. . 1161-1165.

353. Validity, reproducibility, and clinical significance of noninvasive brachi al-ankle pulse wave velocity measurement / A. Yamashina, H. Tomiyama, K. Takeda [et al.] // Hypertens. Res. 2002. Vol. 25. P. 359-364.

354. Vanhoutte, P.M. Other endothelium-derived vasoactive factors / P.M.

Vanhoutte // Circulation. 1993. Vol. 87(Suppl.V). .9-17.

355. Warner, T.D. Relationships between the endothelin and nitric oxide pathways / T.D. Warner // Clin. Exp. Pharmacol. Physiol. 1999. Vol.26, N 3.

P.247-252.

356. Wever, R. Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction? / R. Wever, E. Stoes, T.J. Rabelink // Atherosclerosis. 1998. Vol.

137 (Suppl.). P. 51S-60S.

357. Witztum, J.L. Role of oxidized low-density lipoprotein in atherogenesis / J.L.Witztum, D. Steinberg // J. Clin. Invest. 1991. Vol. 88. P. 1785-1792.

358. Young, D.S. Effects of disease on clinical laboratory tests / D.S. Young, R.B. Friedman 4th ed. Washington :AACC Press, 2001. 2200 p.



Pages:     | 1 |   ...   | 2 | 3 ||
 
 >>  ()





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .